The ability of vitamin D to reduce the secretion of CCL2 in TPC-1 and 8505C cells should not be underestimated, in view of the several pro-tumorigenic effects exerted by CCL2 within the tumor microenvironment and by the therapeutic benefits produced by strategies aimed at reducing its biological effect. This evidence concerns the gene CCL2 and neoplasm.